Ionis Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 896.55, 1489.45, 2174.16, 2981.93, 3757.37 ], "ebit_estimate": [ -621.74, -245.73, 296.92, 933.11, 1655.25 ], "ebitda_estimate": [ -581.47, -230.28, 44.84, 214.04, 567.44 ], "net_income_estimate": [ -602.43, -233.21, 200.01, 818.77, 1358.83 ], "per_share_eps_estimate": [ -3.59, -1.31, 1.04, 4.14, 7.57 ], "eps_nri_estimate": [ -3.63, -1.59, 1.12, 4.62, 7.42 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 0.24, 0.21, 2, null, null ], "pretax_income_estimate": [ -596.64, -176.83, 345.92, 936.98, 1727.49 ], "operating_cash_flow_per_share_estimate": [ -5.03, 0.54, 1.95, null, null ], "roa_estimate": [ -21.75, -10.8, -7.75, 5.2, 14 ], "roe_estimate": [ -190.95, -284.79, 306.33, -16.1, -104.1 ], "gross_margin_estimate": [ 96.36, 92.24, 89.7, 88.5, 88 ], "operating_cash_flow_estimate": [ -829.32, 88.21, 321.5, null, null ], "pettm_estimate": [ 0, 0, 55.96, 14.08, 7.7 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "35.13", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 35.13, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -3.13, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 189.74, 202.62, 252.48, 263.02, 292.1, 382.23, 524.14 ], "ebit_estimate": [ -182.22, -181.71, -150.39, -150.76, -103.79, 1.19, 55.6 ], "ebitda_estimate": [ -176.25, -195.09, -149.34, -202.46, null, null, null ], "net_income_estimate": [ -179.78, -178.72, -150.5, -114.19, -106.79, 8.8, 37.1 ], "per_share_eps_estimate": [ -1.09, -1.07, -0.87, -0.61, -0.48, -0.12, 0.11 ], "eps_nri_estimate": [ -1.09, -1.09, -0.88, -0.72, -0.48, -0.12, 0.11 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -179.85, -176.63, -147.41, -101.03, -80.77, -12.11, 27.5 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 98, 97, 96, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "35.13", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 35.13, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -3.13, "future_operating_cash_flow_per_share_estimate_growth": null }